



Around the world: access to therapy

Introduction - Massimo Colombo (Italy)

Western Countries

Chair: Massimo Colombo (Italy)

Speakers: Maria Buti (Spain), Antonio Craxi (Italy), Graham Foster (UK), Michael Fried (USA), Victor de Ledinghen (France), Stefan Zeuzem (Germany)

Other Countries

Chair: Michael Fried (USA)

Speakers: Mustapha Benazzouz (Morocco), Robert Flisiak (Poland), Jinlin Hou (UK), Vasily Isakov (Russia), Adriana Popescu (Romania), Raymundo Parana Filho (Brazil)

Current situation of hepatitis C in Germany

- ✓ Prevalence: 0.3% (probably PWID, prisoners, homeless, refugees, etc. not appropriately reflected)
- ✓ Total number of patients: 250.000
- ✓ Mortality: HCV infection not covered on death certificates
- ✓ Number of liver transplantations: very low waiting time, therefore almost all patients with SVR on waiting list
- ✓ Total number of patients treated so far: 30-40%
- ✓ Total number of patients treated per year: 40.000

Ressources currently available (Germany)

- ✓ Current resources provided by Health Authorities (amount in euros): € 1.100.000.000 (statutory health insurance)
- ✓ Drugs available: all regimen available
- ✓ Plans for screening: under consideration by the G-BA (German joint federal committee)
- ✓ Plans for access to treatment: unrestricted access to every HCV-infected (health-insured) patient

Actions planned (Germany)

- ✓ To improve screening: awaiting decision of G-BA
- ✓ To facilitate access to treatment: no legal issues, but still some hesitation of physicians
- ✓ Future drugs available: all drugs will be immediately available with EU approval
- ✓ Major future actions planned against hepatitis C: local activities in metropolitan areas to increase awareness and anti-HCV testing